Teva Pharmaceutical Industries (NYSE:TEVA) Posts Earnings Results, Hits Estimates

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) posted its quarterly earnings data on Tuesday. The company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55, MarketWatch Earnings reports. The business had revenue of $3.66 billion for the quarter, compared to analyst estimates of $3.75 billion. Teva Pharmaceutical Industries had a return on equity of 24.40% and a net margin of 2.63%. The firm’s revenue for the quarter was down 8.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. Teva Pharmaceutical Industries updated its FY22 guidance to $2.40-2.60 EPS.

Shares of TEVA traded up $0.16 on Tuesday, hitting $8.69. The company’s stock had a trading volume of 415,934 shares, compared to its average volume of 7,503,947. The company has a market capitalization of $9.59 billion, a PE ratio of 22.45, a PEG ratio of 0.98 and a beta of 1.17. The company has a debt-to-equity ratio of 1.92, a current ratio of 1.14 and a quick ratio of 0.79. Teva Pharmaceutical Industries has a fifty-two week low of $7.24 and a fifty-two week high of $11.55. The company has a 50 day moving average price of $8.74 and a 200 day moving average price of $8.74.

In related news, VP David Matthew Stark sold 6,452 shares of the firm’s stock in a transaction dated Monday, February 28th. The stock was sold at an average price of $8.14, for a total value of $52,519.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sven Dethlefs sold 4,138 shares of the firm’s stock in a transaction dated Wednesday, February 9th. The shares were sold at an average price of $9.06, for a total value of $37,490.28. The disclosure for this sale can be found here. Insiders sold a total of 22,011 shares of company stock worth $188,598 over the last three months. 0.74% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,793,200 shares of the company’s stock valued at $17,467,000 after acquiring an additional 32,617 shares during the last quarter. Nuveen Asset Management LLC grew its position in shares of Teva Pharmaceutical Industries by 15.6% in the 4th quarter. Nuveen Asset Management LLC now owns 1,547,903 shares of the company’s stock valued at $12,399,000 after purchasing an additional 209,321 shares during the period. California State Teachers Retirement System grew its position in shares of Teva Pharmaceutical Industries by 12.2% in the 4th quarter. California State Teachers Retirement System now owns 1,211,298 shares of the company’s stock valued at $9,702,000 after purchasing an additional 131,816 shares during the period. Marshall Wace LLP grew its position in shares of Teva Pharmaceutical Industries by 5,299.1% in the 4th quarter. Marshall Wace LLP now owns 1,049,916 shares of the company’s stock valued at $8,409,000 after purchasing an additional 1,030,470 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Teva Pharmaceutical Industries by 137.1% in the 4th quarter. Alliancebernstein L.P. now owns 669,982 shares of the company’s stock valued at $5,367,000 after purchasing an additional 387,389 shares during the period. 45.79% of the stock is owned by institutional investors.

A number of research firms have recently commented on TEVA. Barclays upgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $11.00 to $13.00 in a research note on Tuesday, April 5th. Argus lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday, January 27th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, April 5th. Sanford C. Bernstein upgraded Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $11.00 price target on the stock in a research note on Friday, March 25th. Finally, Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a $11.00 price target on the stock in a research note on Tuesday, April 12th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $11.83.

Teva Pharmaceutical Industries Company Profile (Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Recommended Stories

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.